I manage purchasing for a mid-sized medical facility. Roughly 60–80 orders a year across all departments. Actually, closer to 90 in a busy year when capital expenditure budgets get approved. When I took over this role in 2020, the CFO gave me one directive: find savings wherever you can.
That almost got me fired.
Well—not literally. But it cost us real money, a few stressful weeks, and some credibility with our clinical team. After five years of buying everything from BTL aesthetic devices to standard vital signs monitors, I've learned that the problem in medical device procurement is rarely what it looks like.
The Surface Problem: Everyone Thinks It's About Price
When people hear I buy medical devices, they ask the same question. How do you get the best price? And yes, price matters. In 2024, we negotiated an 11% reduction on our standard supply contract through better volume pricing. That felt good.
But price was never the real problem. We were chasing penny savings while the big costs were hiding somewhere else entirely.
The first time this hit me was a vital signs monitor order in late 2021.
A department manager asked me to find a cheaper patient monitor. The existing one was aging out, and the upgrade quote from the incumbent was steep. I sourced an alternative that looked nearly identical on the spec sheet. Same parameters. Same certifications. Roughly 30% cheaper. Seemed like a no-brainer.
It took five months to regret that decision.
The cheaper monitor needed calibration every three months instead of every twelve. The manufacturer's service line was essentially a mailbox—48 hours between responses, and that was labeled “premium support.” The training video referenced a different software version than what we received. Our nurses stopped using the features they didn't fully trust. I checked the usage logs later; most of the advanced parameters were never touched.
The cost difference over 18 months: the “cheap” monitor cost us roughly 15% more than the incumbent would have. And that was before counting staff time.
Deep Cause #1: We Compare Prices, Not Total Cost
Everything I’d read about procurement said the same thing: get three quotes, compare apples to apples, pick the lowest compliant bid. In practice, for our facility, the lowest compliant bid was the most dangerous option.
Total cost of ownership isn't just the machine. It's:
- Service contracts and response time guarantees
- Calibration frequency and associated costs
- Consumables—some devices only work with proprietary supplies
- Staff training and onboarding complexity
- Downtime and what a failed device costs in cancelled procedures
- Integration with existing systems (the silent killer)
That last one got us in 2023. We had to pass on what looked like a fantastic deal for a patient monitoring add-on because the data format didn't integrate with our EMR. The “software adapter” would have added $8,000. The vendor offered to “build something custom” for another $14,000. (Note to self: always ask about integration before you fall in love with a quote.)
Deep Cause #2: You're Buying a Device, Not Supporting a Procedure
Here's the lesson that took me the longest to learn. You are not buying a piece of equipment. You are buying support for a clinical procedure performed by a human being with years of training and particular habits.
A good example from outside my usual scope: our affiliated ophthalmic center was upgrading their surgical platform. I was brought in to evaluate bids. On paper, I compared energy profiles, console dimensions, and warranty terms. Then a surgeon stopped me. She said, “Let me walk you through how an IOL is implanted. Then you'll understand what we actually need.”
In cataract surgery, the surgeon opens the lens capsule, uses phacoemulsification to break up the cloudy lens, and then implants the intraocular lens through a tiny incision. A safe IOL implantation depends on consistent intraocular pressure, continuous irrigation, and a phaco handpiece that doesn't surge or chatter. Any pressure fluctuation can compromise the delicate capsular bag.
What did that have to do with my purchasing analysis? Everything. The cheaper surgical platform had noticeably weaker fluidics management. In most routine cases, it would have been fine. In dense cataracts, the surge risk was higher. That margin of risk isn't worth saving $9,000 on a platform that will be used 10,000 times over its lifespan.
People think an expensive device produces better outcomes. That's backwards. You choose the device that supports the procedure correctly. If it costs more, it's not “expensive.” It's appropriately priced.
Deep Cause #3: Fragmented Buying Is an Outdated Model
This is where my thinking has changed the most. In 2020, I was taught “best-in-breed” purchasing: the best monitor from one manufacturer, the best aesthetic device from another, the best surgical platform from a third. That made sense when devices were standalone boxes with separate workflows and no data sharing.
The industry has moved on. Device categories are converging. As of 2025, our facility buys aesthetic equipment, surgical platforms, diagnostic imaging, and patient monitoring—and increasingly, these need to coexist on the same network. What was best practice in 2020 may not apply in 2025.
That changes how you evaluate brands. Take BTL, for example. The brand started in aesthetics with devices like the BTL Emsculpt machine—a non-invasive body contouring system that uses focused electromagnetic energy. Ten years ago, you could have dismissed BTL as a single-category aesthetic player. Today, the BTL brands portfolio spans aesthetic devices, surgical energy platforms, and diagnostic equipment.
So when I evaluate a BTL Emsculpt machine quote now, I'm not just comparing body contouring specs. I'm asking whether that manufacturer has the regulatory footprint, service network, and product roadmap to support a long-term relationship across categories. The question I ask about any vendor isn't “Are they good at X?” It's “Where will they be in ten years when this device needs parts, updates, and integration?”
The CPAP machine market made this painfully obvious.
The CPAP Reality Check
You'd think no device could be more commoditized than a CPAP machine. Standard pressure settings. Long lists of approved manufacturers. Broadly similar features. In early 2023, we sourced a batch of lower-cost CPAP units for our sleep medicine program. On the spec sheet, they matched every requirement: compatible with standard masks, correct pressure range, basic data reporting.
Except the data reporting wasn't compliant with our reimbursement documentation. Our team had to manually transcribe compliance data—hours per patient per month. And the noise profile was noticeably louder than the incumbent. Two patients refused to continue their home trials.
The real disaster was subtler. When the 2021 CPAP recall wave reshaped the market, our “cheap” vendor became far more expensive. Recall management, replacement logistics, and regulatory paperwork all fell on us. We were saving $50 per unit on a clinical asset that needed ongoing regulatory attention. (Should mention: per FDA recall guidance, facilities must verify device status regularly—check current records at accessdata.fda.gov before purchasing any affected category.)
The lesson: compliance, data integrity, and manufacturer staying power are part of the device. If you ignore them, you have only yourself to blame. Everything is connected to something, whether you planned for it or not.
What This Cost Us
Let me put the mistakes in numbers:
- $2,400 in extra calibration and service fees on the “cheaper” vital signs monitor (ugh)
- 120+ staff hours on manual CPAP data transcription and retraining
- $8,000 for the EMR integration adapter we should have budgeted from the start
- One very awkward meeting with the VP of operations when patient data wasn't appearing in the EMR on time
Then the soft costs. Nurse frustration. Surgeon skepticism about my judgment. A procurement process that clinicians now felt they needed to double-check.
That last one hurt the most. Trust, once dented, doesn't come back on the next purchase order.
What We Do Now (The Simple Fix)
After our 2024 vendor consolidation project, the evaluation framework changed. Five questions, in order:
- Walk me through the procedure this device supports. Draw the workflow. If you can't explain how an IOL is implanted, you shouldn't be choosing the phaco platform. Same principle applies to every purchase—let a clinician walk you through the steps before you look at prices.
- Show me the full three-year cost. Quote must include service, calibrations, consumables, integration, training, and expected downtime.
- Prove the service infrastructure. Response times in writing. Real humans, not a mailbox.
- Evaluate the platform, not just the product. Does this manufacturer have staying power across the categories we need, from aesthetic devices to patient monitoring?
- Verify regulatory status. FDA clearance, CE marking, and the manufacturer's recall history—including how they handled it.
We don't always buy the cheapest option anymore. We don't always buy the most expensive either. We buy the device that fits.
The fundamentals haven't changed—it's still about patient outcomes and responsible spending. But the execution has transformed. The old playbook of independent quotes and fragmented categories is exactly how you end up with a $35,000 mistake that saves $2,000.
Price is what you pay. The procedure is what you get. The device is just the tool that connects them.
